Highnoon Laboratories – a leader in the development, marketing, and distribution of modern, high-quality, and affordable medicines – has made it once again to the coveted “Forbes Asia’s Best Under a Billion 2021” list. Highnoon is the only pharmaceutical company from Pakistan to be awarded such an accolade this year.
Although Highnoon Laboratories Limited has had the honor of being a part of the same Forbes list in 2019 as well, it says the latest accolade is different. Two years back, the world had not yet been hit by the pandemic of Covid-19; soon after, most of the businesses around the world were severely impacted by Covid, but Highnoon says it not only survived, but also improved its performance.
Another highlight this year is that Highnoon is the only pharmaceutical company from Pakistan that has made it to the ‘Forbes Best Under a Billion’ list. This is a testament to the fact that the company is showing promise and commitment to patient well-being and consequently earning the trust of millions of people suffering from health problems.
Marking this accolade as one of the most defining moments for the company to date, Chairman Highnoon, Tausif Khan, shares, “Nothing makes me happier than seeing our company rising against all odds. This success has many contributing factors and I would like to extend my heartfelt gratitude to every single stakeholder for their tireless efforts and giving their absolute 100%.”
“Our valued shareholders, medical fraternity and health practitioners, our leadership and most importantly our heroes; the workforce, is the most prized possession and asset of this company,” he adds.
At a time when many companies were right-sizing, down-sizing or even shutting down, Highnoon still played its part in supporting the healthcare industry and giving Pakistan’s economy the push it needed during this difficult time. With this and various other milestones under its belt, Highnoon believes that it is on the right track to making greater achievements and pursuing excellence in the field.
Forbes is an American business magazine. Published bi-weekly, it features original articles on finance, industry, investing, and marketing topics. Forbes ‘Best Under A Billion’ list highlights the 200 high-performing Asia-Pacific companies with revenue under $1 billion.
